Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GlucoNorm · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 2. | EXPERIMENTAL | GlucoNorm |
| 1. | EXPERIMENTAL | Glyburide |
| Name | Type | Description |
|---|---|---|
| glyburide | DRUG | Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test. |
| GlucoNorm | DRUG | Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test. |
Inclusion Criteria: * Type 2 diabetes \> 3 months duration * Male or female * Over 65 years of age * Diet controlled only * HgbA1C \< 8.5% Exclusion Criteria: * Treatment with oral hypoglycemic agents or insulin or the likelihood of requiring treatment with these during the study. * Anemia - hgb ...
Top 16 of 30 competitors
GlucoNorm is being studied for the treatment of Type 2 Diabetes. It is an investigational small molecule developed by Novo Nordisk A/S. The clinical program has focused on elderly patients with Type 2 Diabetes, specifically evaluating effects on post-prandial hyperglycemia, which is elevated blood sugar after meals.
GlucoNorm is developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical program for this investigational small molecule in Type 2 Diabetes.
GlucoNorm is in Phase 2 clinical development. It has not been approved by the FDA and remains an investigational therapy for Type 2 Diabetes. The Phase 2 program includes one completed trial, and no active trials are currently listed for this asset.
GlucoNorm has been evaluated in one completed Phase 2 trial, NCT00451620, titled Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes. The trial enrolled 30 participants in Canada, was randomized and controlled, and included subjects aged 65 years and older.
The GlucoNorm Phase 2 trial NCT00451620 was a randomized, controlled study comparing GlucoNorm with glyburide in elderly subjects with Type 2 Diabetes. It enrolled 30 participants aged 65 years and older in Canada and assessed post-prandial hyperglycemia. The study was completed and was not double-blind.